Clinical Trials
21 trialsNCT02688803 2025-12-04
OTT15-04
Ottawa Hospital Research Institute
Phase 4 Terminated
NCT01358877 2025-11-28
APHINITY
Hoffmann-La Roche
Phase 3 Completed
NCT00630032 2024-02-21
TavIx
UNICANCER
Phase 3 Completed
NCT00121992 2023-04-04
Docetaxel, Doxorubicin (A), Cyclophosphamide (C) (TAC) vs 5-Fluorouracil, A, C (5FAC) Breast Cancer Adjuvant Treatment
Spanish Breast Cancer Research Group
Phase 3 Completed
NCT01036087 2023-03-30
Panitumumab, Nab-paclitaxel and Carboplatin for HER2 Negative Inflammatory Breast Cancer
M.D. Anderson Cancer Center
Phase 2 Completed
NCT00129389 2023-03-07
FAC Versus FAC Plus Weekly Paclitaxel as Adjuvant Treatment of Node Negative High Risk Breast Cancer Patients
Spanish Breast Cancer Research Group
Phase 3 Completed
NCT01779050 2022-11-01
Effect of Trastuzumab on Disease Free Survival in Early Stage HER2-Negative Breast Cancer Patients With ERBB2 Expressing Disseminated Tumor Cells
Washington University School of Medicine
Phase 2 Terminated
NCT00087178 2022-08-11
Comparison of Two Combination Chemotherapy Regimens in Treating Women With Breast Cancer
NSABP Foundation Inc
Phase 3 Completed
NCT01966471 2022-06-14
A Study of Trastuzumab Emtansine (Kadcyla) Plus Pertuzumab (Perjeta) Following Anthracyclines in Comparison With Trastuzumab (Herceptin) Plus Pertuzumab and a Taxane Following Anthracyclines as Adjuvant Therapy in Participants With Operable HER2-Positive Primary Breast Cancer
Hoffmann-La Roche
Phase 3 Completed
NCT01593020 2021-09-22
Neoadjuvant Study of Sequential Eribulin Followed by FAC Compared to Sequential Paclitaxel Followed by FEC in Early Stage Breast Cancer Not Overexpressing HER-2
M.D. Anderson Cancer Center
Phase 2 Completed
NCT02132949 2021-09-17
BERENICE
Hoffmann-La Roche
Phase 2 Completed
NCT01220128 2021-05-25
INDUCT
GlaxoSmithKline
Phase 2 Terminated
NCT00014222 2020-10-05
Combination Chemotherapy With or Without Colony-stimulating Factors in Treating Women With Breast Cancer
Canadian Cancer Trials Group
Phase 3 Completed
NCT01803282 2020-06-02
Study to Evaluate the Safety and Tolerability of Andecaliximab as Monotherapy and in Combination With Chemotherapy in Participants With Advanced Solid Tumors
Gilead Sciences
Phase 1 Completed
NCT00559845 2018-04-09
A Study of Avastin (Bevacizumab) in Patients With Inflammatory or Locally Advanced Breast Cancer
Hoffmann-La Roche
Phase 2 Completed
NCT00950300 2018-01-23
A Study to Compare Subcutaneous (SC) Versus Intravenous (IV) Administration of Herceptin (Trastuzumab) in Women With Human Epidermal Growth Factor Receptor (HER) 2-Positive Early Breast Cancer
Hoffmann-La Roche
Phase 3 Completed
NCT00615901 2017-03-03
Dose Dense Adjuvant CMF (Cyclophosphamide, Methotrexate, Fluorouracil) at 14 and 10-11 Day Intervals for Women With Early Stage Breast Cancer
Memorial Sloan Kettering Cancer Center
Phase NA Completed
NCT00499603 2016-11-01
Paclitaxel Followed by FEC Versus Paclitaxel and RAD001 Followed by FEC In Women With Breast Cancer
M.D. Anderson Cancer Center
Phase 2 Unknown
NCT00429299 2016-03-22
CHERLOB
GlaxoSmithKline
Phase 2 Completed
NCT00756470 2014-11-17
Phase II Neoadjuvant in Inflammatory Breast Cancer
M.D. Anderson Cancer Center
Phase 2 Terminated
NCT00688740 2011-02-16
TAX316
Sanofi
Phase 3 Completed